Journal of Cancer Research and Cellular Interventions (JCCRCI)

OLITES PUBLISHERS
A Global Approach For Research

Open Access

Short Review

Reframing Hepatocellular Carcinoma: From Tumor-Centric Views to Ecosystem-Based Oncology

Santol D, Cucchetti F, Padbury U, Obour E, Babicki R, Hirasawa R
Collaboration Research Center for Precision Oncology Based Omics-PKR PrOmics, Indonesia
* **Corresponding Author:** Padbury U, Collaboration Research Center for Precision Oncology Based Omics-PKR PrOmics, Indonesia
Citation: Padbury U (2025). Reframing Hepatocellular Carcinoma: From Tumor-Centric Views to Ecosystem-Based Oncology V1(3)
Copyright: © 2025 Padbury U, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received date: December10, 2025: **Accepted date**: December18, 2025: **Published date:** December 29,2025

Keywords: systems biology, immunometabolism, microenvironmental dynamics, oncogenic mutations, heterogeneity

Abstract

Hepatocellular carcinoma (HCC), the most common primary liver malignancy, has long been studied through a tumor-centric lens focusing on genetic mutations and cellular proliferation. However, emerging evidence suggests that HCC is better understood as a complex ecosystem shaped by chronic inflammation, metabolic dysregulation, immune interactions, and microenvironmental dynamics. This article presents a new perspective that reframes HCC as an ecological disease, where tumor cells coexist and co-evolve with stromal, immune, and hepatic components. By integrating insights from systems biology, immunometabolism, and precision medicine, this approach highlights novel therapeutic opportunities that extend beyond conventional treatments. The ecosystem-based model not only enhances our understanding of disease progression but also paves the way for more personalized, adaptive, and effective strategies in HCC management.

Introduction

Hepatocellular Carcinoma (HCC) accounts for nearly 90% of all primary liver cancers and remains a leading cause of cancer-related mortality worldwide. Traditionally, research has emphasized oncogenic mutations, viral etiologies such as hepatitis B and C, and cirrhosis as primary drivers. While these factors are critical, they do not fully explain the heterogeneity in disease progression and treatment response

The Tumor as an Ecosystem

The liver is inherently a complex organ, constantly exposed to metabolic, toxic, and immunological challenges. In chronic liver disease, this environment becomes altered, giving rise to a “pre-cancerous niche.”

- **Tumor cells** act as invasive species.
- **Immune cells** (e.g., T cells, macrophages) serve as regulators or enforcers.
- **Stromal cells** provide structural and biochemical support.
- **Extracellular matrix** shapes the physical habitat.

This interplay determines tumor survival, growth, and resistance to therapy

Chronic Inflammation as the Soil of Carcinogenesis

Unlike many cancers, HCC almost always arises in the context of chronic inflammation. Conditions such as viral hepatitis, alcohol-induced liver injury, and non-alcoholic fatty liver disease create a persistent inflammatory state

This environment leads to:

- Continuous hepatocyte damage and regeneration
- DNA mutations and epigenetic alterations

- Immune exhaustion and tolerance

Thus, inflammation acts not just as a trigger, but as a sustaining force in tumor evolution.

Immunometabolism: The Hidden Driver

A novel aspect of HCC research lies in immunometabolism—the intersection of metabolic pathways and immune function

Key insights include

- Tumor cells compete with immune cells for nutrients like glucose and amino acids
- Hypoxic conditions favor tumor survival while impairing immune response
- Lipid accumulation in the liver alters immune signaling

This metabolic competition creates an imbalance that favors tumor persistence.

Microenvironmental Plasticity and Therapy Resistance

- Tumors adapt to anti-angiogenic therapies by activating alternative pathways
- Immune checkpoint inhibitors may fail due to immune exclusion or suppression
- Stromal remodeling can shield tumor cells from drugs

Thus, targeting the tumor alone is insufficient—interventions must disrupt the entire ecosystem.

Toward Ecosystem-Based Therapeutics

This new perspective opens the door to innovative treatment strategies:

1. Combination Therapies

Integrating immunotherapy, metabolic modulators, and anti-fibrotic agents to target multiple ecosystem components simultaneously.

2. Microbiome Modulation

Emerging studies suggest gut-liver axis involvement in HCC, where microbiota influence immune responses and inflammation.

3. Adaptive Treatment Models

Using real-time biomarkers and AI-driven models to adjust therapy based on ecosystem changes

4. Preventive Ecosystem Engineering

Early interventions in high-risk patients to restore liver homeostasis and prevent tumor emergence

Future Directions

The ecosystem model encourages interdisciplinary research combining oncology, immunology, systems biology, and computational science. Future work should focus on

- Mapping cellular interactions at single-cell resolution
- Identifying ecosystem biomarkers for early detection
- Designing therapies that reprogram rather than destroy the tumor environment

Conclusion

Reframing Hepatocellular Carcinoma as an ecosystem rather than a standalone tumor represents a transformative shift in oncology. This perspective not only deepens our understanding of disease biology but also redefines therapeutic goals—from eradication to ecological balance. As research progresses, ecosystem-based oncology may become the cornerstone of personalized medicine in liver cancer care

Reference

1. Skånberg, J.; Lundholm, K.; Haglind, E. Effects of blood transfusion with leucocyte depletion on length of hospital stay, respiratory assistance and survival after curative surgery for colorectal cancer. Acta Oncol. 2007, 46, 1123–1130.
2. Barbuti, A.M.; Chen, Z.S. Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. Cancers 2015, 7, 2360–2371.
3. Ojima, I.; Wang, X.; Jing, Y.; Wang, C. Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery. J. Nat. Prod. 2018, 81, 703–721.
4. Daniel, P.; Balušíková, K.; Truksa, J.; Černý, J, et al. Effect of substituents at the C3', C3'N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells. Toxicol. Appl. Pharmacol. 2024, 489, 116993.

5. Ramnath, N.; Hamm, J.; Schwartz, G.; Holden, S.; Eckhardt, S.G, et al phase I and pharmacokinetic study of BAY59: A novel taxane. Oncology 2004, 67, 123–129.
6. 6McQuade, J.L.; Posada, L.P.; Lecagoonporn, S.; Cain, S.; Bassett, R.L., Jr.; Patel, S.P.; Hwu, W.J.; Hwu, P.; Davies, M.A.; Bedikian, A.Y.; et al. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016, 26, 604–608.
7. Donnez, J.; Dolmans, M.M.; Demylle, D.; Jadoul, P.; Pirard, C.; Squifflet, J.; Martinez-Madrid, B.; Van Langendonckt, A. Restoration of ovarian function after orthotopic (intraovarian and periovarian) transplantation of cryopreserved ovarian tissue in a woman treated by bone marrow transplantation for sickle cell anaemia: Case report. Hum. Reprod. 2006, 21, 183–188

Journal of Cancer Research and Cellular Interventions (JCCRCI)

ThisworkislicensedunderCreative CommonsAttribution 4.0 License
DOI:10/JCCRCI/2025/015

Your next submission with

OlitesPublisherswillreachyouthebelowassets

- We follow principles of publicationledbythe CommitteeonPublicationEthics(COPE).
- Doubleblindedpeerreviewprocesswhichis justaswellasconstructive.
- Permanent archiving of yourarticle onourwebsite
- QualityEditorialservice
- Manuscriptaccessibilityindifferent formats(PDF,FullText)
- authorsretaincopyrights
- uniqueDOIforallarticles
- immediate,unrestrictedonlineaccess

Learn more: Journal of Cancer Research and Cellular Interventions Olites Publishers (olitespublishing.org)